Immunohistochemistry Market | CAGR of 7.3% | Global Forecast to 2021

According to the new market research report "Immunohistochemistry Market by Product (Antibody, Reagent, Kits, Slide Staining System, Tissue Microarray) Application (Diagnostics (Cancer, Cardiovascular, Diabetes, Autoimmune, Infectious Diseases) & Drug Testing) End User – Global Forecast to 2021?, published by MarketsandMarkets™, analyzes and studies the major market drivers, restraints/challenges, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the world (RoW).

Don’t miss out on business opportunities in Immunohistochemistry Market.

Speak to our analyst and gain crucial industry insights that will help your business grow:https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=121632939

The immunohistochemistry market is projected to reach USD 2.12 Billion by 2021, at a CAGR of 7.3% during the forecast period. Rising geriatric population, growing prevalence of chronic diseases, increasing number of diagnostic centers, and increasing physician awareness & demand for histopathology are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine offer significant growth opportunities in the market.

Immunohistochemistry (IHC) is a laboratory test that uses antibodies to test certain antigens in a tissue combining immunological, anatomical, and biochemical techniques. There are multiple approaches and permutation in immunohistochemistry applicable in drug testing and diagnosis of chronic diseases like cancer, infectious diseases, cardiovascular diseases, diabetes, and autoimmune diseases. The market covers the market size from 2014 to 2021.

Browse and in-depth TOC on " Immunohistochemistry Market"

181 – Tables

44 – Figures

225 – Pages

Request for Sample Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=121632939

Rising geriatric population, growing prevalence of chronic diseases, rapid technological developments in the IVD industry, and increasing healthcare spending are expected to fuel the growth of this market in the coming years. However, rapid growth in the developing countries across APAC and Latin America and the increasing demand for personalized medicine are expected to offer significant growth opportunities for players in the market. Regulatory restrictions in developed countries, however, are a major challenge faced by market players in the current market.

Download an Illustrative overview of the report @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=121632939

Key Players:

The major players in the immunohistochemistry market are F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck Millipore (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Abcam plc (U.K.), Cell Signaling Technology, Inc. (U.S.), and Bio SB Inc. (U.S.).

F. Hoffman-La Roche AG commanded a share of 22.1% of the global immunohistochemistry market in 2015. The company is a leading immunohistochemistry product manufacturer and supplies its products to hospitals, research laboratories, pharmaceutical companies, and contract research organizations. Roche mainly focuses on acquisitions as its key business strategy. In line with this strategy, in August 2015, Roche acquired GeneWEAVE BioSciences, Inc. (U.S.), a privately held company focused on innovative clinical microbiology diagnostics solutions. Furthermore, in December 2014, the company acquired GeneWEAVE BioSciences, Inc. (U.S.), a privately held company focused on innovative clinical microbiology diagnostics solutions, and Ariosa Diagnostics, Inc. (U.S.), a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing (NIPT) service through its CLIA laboratory using cell-free DNA (cfDNA) technology. This acquisition strengthened Roche's immunohistochemistry and tissue diagnostic business. Roche Diagnostics also focuses on expanding its business globally in order to strengthen its position in the immunohistochemistry market. The company aims to expand its business in high-growth regions such as the Middle East and Africa, Asia-Pacific, and Latin America. Currently, the geographic segments of Europe and North America account for about 68% of the company’s diagnostics business. Furthermore, the company has a strong product portfolio for immunohistochemistry, which comprises antibodies, detection systems, blockers, antibodies diluents, and other ancillaries.

Latest news about market research and trends.